# Forensic Dossier: Study Forensics: Amyloid-targeting antibody improves biomarkers without cognitive benefit

**Run ID:** `mech_study-forensics-029_claude_haiku_4fb4e3`  
**Task:** study-forensics-029 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-06T15:44:11.307205+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** biomarker_without_clinical_benefit  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 9
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 4.5/6 | 5.6/8 | 8.0/8 | 1.5/10 | 10.0/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** cautious_scope_control, none_or_minor, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "solid"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: No match (got: solid)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[4]`: "Checked for decorative uncertainty: The acknowledgment that 'cognitive benefits remain unproven' is substantive, not dec"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "Biomarker measurements (amyloid deposits, neurodegeneration markers) were validated and reliably measured"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[2]`: "Whether the open-label extension is presented as exploratory or as a path to approval (text says 'proposed,' suggesting "
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[1]`: "Mechanism vs. evidence: if the text had proposed a mechanism (e.g., 'amyloid clearance alone is insufficient') without e"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 genuinely diverse alternatives

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[2]`: "Is this a case of 'biomarkers don't equal clinical benefit'? Yes, but that's an honest reporting of the trial result, no"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.70, 469 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'solid'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/8 content words)
  - `key_claims[0]`: "The study found a dissociation: strong biomarker effects but no cognitive benefit"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/7 content words)
  - `key_claims[1]`: "Investigators did NOT overclaim—they explicitly state cognitive benefits are unproven"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/8 content words)
  - `key_claims[2]`: "The null cognitive finding is presented as a genuine failure, not explained away"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/8 content words)
  - `key_claims[3]`: "The open-label extension is proposed but framed as addressing an unproven question, not as confirmat"
- **[WARN]** `[HEURISTIC]` `claim_step_alignment`: Key claim 4 not well supported in reasoning steps (1/8 content words found)
  - `key_claims[3]`: "The open-label extension is proposed but framed as addressing an unproven question, not as confirmat"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "Overclaim: if the text had claimed cognitive benefits based on biomarker improvements, or if investi"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "Mechanism vs. evidence: if the text had proposed a mechanism (e.g., 'amyloid clearance alone is insu"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 3 is stated without rejection reasoning
  - `alternative_hypotheses[2]`: "Correlation vs. causation: if biomarker changes were observational rather than from a randomized tri"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 11248ms

**Final Answer:** solid

**Confidence:** 0.88

**Assumptions:**
- The trial was properly randomized and controlled (Phase 2/3 design implies this)
- Biomarker measurements (amyloid deposits, neurodegeneration markers) were validated and reliably measured
- Cognitive decline was measured using standard, validated instruments
- The trial had adequate statistical power and follow-up duration to detect cognitive effects if present
- The text accurately represents what the investigators concluded

**Reasoning Steps:**
1. Identified the core claim: drug reduced amyloid biomarkers but failed to slow cognitive decline
2. Checked for overclaim: The text does NOT claim cognitive benefit despite biomarker success. Investigators explicitly state cognitive benefits 'remain unproven'
3. Checked for mechanism vs. evidence: The text does not claim a mechanism explaining why biomarkers improved without cognitive benefit. It simply reports both findings
4. Checked for correlation vs. causation: The biomarker improvements are from a randomized trial (appropriate for causal inference about drug effects on biomarkers). The null finding on cognition is also from the same trial
5. Checked for decorative uncertainty: The acknowledgment that 'cognitive benefits remain unproven' is substantive, not decorative—it directly contradicts what one might expect from biomarker success
6. Checked for confounders: In a randomized trial, confounding is controlled by design. The null cognitive finding is not explained away
7. Evaluated the logical coherence: The investigators present a genuine disconnect (biomarker success ≠ cognitive benefit) and acknowledge it rather than overstate implications

**Key Claims:**
- The study found a dissociation: strong biomarker effects but no cognitive benefit
- Investigators did NOT overclaim—they explicitly state cognitive benefits are unproven
- The null cognitive finding is presented as a genuine failure, not explained away
- The open-label extension is proposed but framed as addressing an unproven question, not as confirmation

**Alternative Hypotheses:**
- Overclaim: if the text had claimed cognitive benefits based on biomarker improvements, or if investigators had downplayed the null cognitive finding
- Mechanism vs. evidence: if the text had proposed a mechanism (e.g., 'amyloid clearance alone is insufficient') without evidence, or applied animal findings to humans
- Correlation vs. causation: if biomarker changes were observational rather than from a randomized trial

**Uncertainties:**
- Whether the trial was adequately powered for cognitive outcomes (not stated in the summary)
- Whether follow-up duration was sufficient to detect cognitive decline (not specified)
- Whether the open-label extension is presented as exploratory or as a path to approval (text says 'proposed,' suggesting exploratory)
- The specific cognitive tests used and their sensitivity

**Self-Verification:**
- Did I assume problems that aren't stated? No—the text itself reports the null cognitive finding
- Did I miss an overclaim? No—the investigators acknowledge the disconnect and do not claim cognitive benefit
- Is this a case of 'biomarkers don't equal clinical benefit'? Yes, but that's an honest reporting of the trial result, not an epistemic flaw in the summary
- Could the open-label extension be seen as problematic? It's uncontrolled, but the text frames it as exploratory, not as proof
- Is the summary itself well-calibrated? Yes—it reports both the biomarker success and the cognitive failure without overinterpreting either

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (4.5/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 11.2s | 40.0/100 | 3.6 |

Failure modes observed: named_not_explained, unsupported_conclusion, wrong_answer.
